The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001252303p
Ethics application status
Help: Ethics application status
Not yet submitted
Date submitted
Help: Date submitted
29/09/2026
Date registered
Help: Date registered
14/10/2026
Date last updated
Help: Date last updated
14/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
14/10/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A study of the efficacy of a radiation treatment to help reduce pain in people with pancreatic cancer or radiological evidence of tumour (of any histology) invading the celiac axis
Scientific title
A multi-centre pilot study of 3-fractIoN CEliac Plexus RadioablaTION (INCEPTION): Evaluating the efficacy in reducing pain in adults with pancreatic cancer and cancer-related abdominal pain caused by involvement of the celiac plexus
Additional trial identifiers [1] 318213 0
NIL
Universal Trial Number (UTN)
Trial acronym
INCEPTION
Related trial records

Health condition
Health condition(s) studied:
Malignant Celiac plexus syndrome 343271 0
Pancreatic Cancer 343272 0
Upper abdominal malignancies involving the celiac axis 343273 0
Condition category
Condition code
Cancer 339391 339391 0 0
Pancreatic

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants will receive three-fraction celiac plexus radioablation (CPRS) using stereotactic radiotherapy for the treatment of malignant celiac plexus syndrome. Radiotherapy will be delivered at participating GenesisCare radiation oncology centres by qualified Radiation Oncologists, Radiation Therapists and Medical Physicists experienced in stereotactic radiotherapy. Treatment consists of 36 Gy, 21 Gy and 18 Gy delivered over three fractions, with a minimum of 48 hours between fractions, and is planned using CT simulation and image-guided radiotherapy techniques.

Participants will attend a planning appointment prior to treatment, during which a CT simulation scan is performed to design an individualised treatment plan. Treatment is delivered in person on an outpatient basis. For each treatment fraction, participants will be positioned on the treatment couch and undergo imaging verification to confirm accurate treatment delivery before radiation is administered. Each treatment visit is expected to take approximately 15 to 30 minutes from entering to leaving the treatment room. The actual radiation delivery takes only a few minutes, with the remaining time used for positioning, image guidance and treatment verification.

Participants will receive three radiotherapy treatments over approximately one week, with at least 48 hours between fractions. Adherence to the intervention will be monitored through radiotherapy treatment records, treatment management systems, medical records and study case report forms. Completion of each prescribed fraction, treatment dates, dose delivered, and any treatment interruptions, delays or deviations will be documented and reviewed by the study team. Participants will be monitored throughout the study to assess treatment completion, safety and tolerability. Follow-up assessments will occur approximately 48 hours, 2 weeks, 4 weeks and 3 months after treatment and will include pain assessments, quality of life questionnaires, opioid medication use and safety monitoring.
Intervention code [1] 335112 0
Treatment: Other
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 346589 0
Pain response at 4 weeks following treatment
Timepoint [1] 346589 0
Baseline and 4 weeks after completion of radiotherapy.
Primary outcome [2] 346590 0
Treatment-related Grade 3 or higher toxicity
Timepoint [2] 346590 0
4 weeks after completion of radiotherapy
Secondary outcome [1] 466559 0
Improvement in pain-related symptoms
Timepoint [1] 466559 0
Baseline, 4 weeks and 3 months after completion of radiotherapy.
Secondary outcome [2] 466560 0
Reduction in opioid medication use
Timepoint [2] 466560 0
Baseline, 4 weeks and 3 months after completion of radiotherapy.
Secondary outcome [3] 466561 0
Feasibility of treatment delivery
Timepoint [3] 466561 0
At commencement of radiotherapy treatment
Secondary outcome [4] 466562 0
Grade 1 treatment-related adverse events
Timepoint [4] 466562 0
4 weeks and 3 months after completion of radiotherapy.
Secondary outcome [5] 466563 0
Treatment-related Grade 3 toxicities at 3month follow-up
Timepoint [5] 466563 0
3 months after completion of radiotherapy.
Secondary outcome [6] 468954 0
Grade 2 treatment-related adverse events
Timepoint [6] 468954 0
4 weeks and 3 months after completion of radiotherapy.
Secondary outcome [7] 468959 0
Treatment-related > Grade 3 toxicities at 3month follow-up
Timepoint [7] 468959 0
3 months after completion of radiotherapy.

Eligibility
Key inclusion criteria
Adults aged 18 years or older with pancreatic cancer and cancer-related abdominal pain caused by involvement of the celiac plexus are eligible for this study. Participants must have either biopsy-confirmed pancreatic cancer or imaging evidence of a tumour involving the celiac axis. Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3, be willing and able to provide written informed consent, and be willing and able to comply with all study visits, treatment requirements and follow-up assessments.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Participants will be excluded if they have received prior radiotherapy to the upper abdomen, have tumours directly invading luminal gastrointestinal organs (including fistulas), have an estimated life expectancy of less than 4 weeks, have acute spinal cord compression, have radiosensitising conditions associated with increased radiotherapy toxicity, or are pregnant or breastfeeding

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
This is a prospective Pilot study designed to evaluate the safety, efficacy and feasibility of three-fraction celiac plexus radioablation. A sample size of 20 participants was selected based on expected recruitment feasibility within the target population and the need to generate preliminary safety and efficacy data to inform future larger studies. Participants who withdraw or are lost to follow-up before completing the primary 4-week assessment will be replaced to ensure that 20 evaluable participants complete follow-up. The study will primarily use descriptive analyses to estimate pain response rates and treatment-related toxicity outcomes.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA,VIC
Recruitment hospital [1] 30299 0
GenesisCare - Footscray - Footscray
Recruitment hospital [2] 30300 0
GenesisCare - Wembley - Wembley
Recruitment hospital [3] 30301 0
GenesisCare - Mater Hospital - North Sydney
Recruitment hospital [4] 30302 0
Genesis Cancer Care - Wesley - Auchenflower
Recruitment hospital [5] 30303 0
GenesisCare - Adelaide - Adelaide
Recruitment hospital [6] 30304 0
GenesisCare - St. Vincent's Sydney - Darlinghurst
Recruitment postcode(s) [1] 46711 0
3011 - Footscray
Recruitment postcode(s) [2] 46712 0
6014 - Wembley
Recruitment postcode(s) [3] 46714 0
4066 - Auchenflower
Recruitment postcode(s) [4] 46715 0
5000 - Adelaide
Recruitment postcode(s) [5] 46716 0
2010 - Darlinghurst

Funding & Sponsors
Funding source category [1] 322774 0
Commercial sector/Industry
Name [1] 322774 0
GenesisCare
Country [1] 322774 0
Australia
Funding source category [2] 322777 0
Charities/Societies/Foundations
Name [2] 322777 0
The Royal Australian and New Zealand College of Radiologists
Country [2] 322777 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
GenesisCare
Address
Country
Australia
Secondary sponsor category [1] 325701 0
None
Name [1] 325701 0
Address [1] 325701 0
Country [1] 325701 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 321216 0
St Vincent's Hospital Melbourne Human Research Ethics Committee
Ethics committee address [1] 321216 0
Ethics committee country [1] 321216 0
Australia
Date submitted for ethics approval [1] 321216 0
01/11/2026
Approval date [1] 321216 0
Ethics approval number [1] 321216 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 153034 0
Dr Violet Koh
Address 153034 0
GenesisCare 1/9 Marion St Footscray 3011, Victoria
Country 153034 0
Australia
Phone 153034 0
+61 3 9319 3200
Fax 153034 0
Email 153034 0
Contact person for public queries
Name 153035 0
Angela Benson
Address 153035 0
GenesisCare 1/9 Marion St Footscray 3011, Victoria
Country 153035 0
Australia
Phone 153035 0
+61439731954
Fax 153035 0
Email 153035 0
Contact person for scientific queries
Name 153036 0
Violet Koh
Address 153036 0
GenesisCare 1/9 Marion St Footscray 3011, Victoria
Country 153036 0
Australia
Phone 153036 0
+61 3 9319 3200
Fax 153036 0
Email 153036 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Individual participant data will not be publicly shared. Data will be stored securely and analysed in a de-identified form. Study results will be reported only in aggregate, and no individual participant will be identifiable in publications or presentations. Participant confidentiality will be maintained in accordance with applicable privacy regulations and ethics requirements.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.